TAS0612

TAS0612 is the orally active inhibitor of RSK、AKT and S6K. TAS0612 has antitumor activity[1].

Product Specifications

CAS Number

[2148902-58-1]

UNSPSC

12352005

Target

Akt; Apoptosis; Ribosomal S6 Kinase (RSK)

Type

Reference compound

Related Pathways

Apoptosis; MAPK/ERK Pathway; PI3K/Akt/mTOR

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/tas0612.html

Purity

98.83

Solubility

DMSO : 50 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C1NC2=NC=NC(N3CCC(CC3)C4=NC(C5=NN=C(C(F)(F)F)O5)=CC=C4NCCNC(C)(C)C)=C2C1(C)C

Molecular Formula

C27H34F3N9O2

Molecular Weight

573.61

References & Citations

[1]Koji Ichikawa, et al. TAS0612, a novel RSK, AKT, and S6K inhibitor, exhibits antitumor effects in preclinical tumor models. Mol Cancer Ther. 2023.|[2]Katsuragawa-Taminishi Y, et al., Triple targeting of RSK, AKT, and S6K as pivotal downstream effectors of PDPK1 by TAS0612 in B-cell lymphomas. Cancer Sci. 2023 Dec;114 (12) :4691-4705.|[3]Okamoto H, et al., Robust anti-myeloma effect of TAS0612, an RSK/AKT/S6K inhibitor, with venetoclax regardless of cytogenetic abnormalities. Leukemia. 2025 Jan;39 (1) :211-221.